A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK

By Tilden Dominic P.  

PharmacoEconomics, Vol. 25, Iss. 1, 2007-01 ,pp. : 39-54

Adis International

Access to resources Recommend Favorite

Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome

By Derosa G   D'Angelo A   Ragonesi PD   Ciccarelli L   Piccinni MN   Pricolo F   Salvadeo S   Montagna L   Gravina A   Ferrari I   Galli S   Paniga S   Cicero AFG  

The Journal of International Medical Research, Vol. 34, Iss. 5, 2006-09 ,pp. : 545-555

Field House Publishing

Access to resources Recommend Favorite

Pioglitazone pays dividends in type 2 diabetes mellitus

By  

Inpharma, Vol. 1, Iss. 1612, 2007-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Pioglitazone pays dividends in type 2 diabetes mellitus

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 540, 2007-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Pioglitazone wins out over rosiglitazone in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1571, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite